TD Securities analyst Jonathan Kelcher maintains Equinix (NASDAQ:EQIX) with a Hold and raises the price target from $875 to $900.
Credit Suisse Maintains Outperform on Spruce Biosciences, Lowers Price Target to $6
Credit Suisse analyst Tiago Fauth maintains Spruce Biosciences (NASDAQ:SPRB) with a Outperform and lowers the price target from $26 to $6.